{"id":"641179826954-41","name":"Newron Pharmaceuticals","registrationDate":"2017-04-27T17:04:32.899+01:00","category":2,"subCategory":3,"legal":"SpA","web":"http://www.newron.com","country":"Italy","headAddress":"Via Ludovico Ariosto, 21","headCity":"Bresso (MI)","headPostCode":"20091","headPhone":"(39)02 61 03 46 09","boss":"Marco Caremi","bossTitle":"Mr","bossPosition":"Executive Vice President Business Development","membersCount":8,"membersFTE":"5.25","membership":"","memberOrga":"http://www.newron.com/ENG/Default.aspx?PAG=78","goal":"Newron is becoming a leader in the development of innovative therapies for Central Nervous System (CNS) disorders and pain, and is committed to improving the quality of life of patients. Our team have built a well-balanced pipeline that embodies highly developed novel therapies for rare CNS diseases, specifically, innovative compounds at different stages of development.","acronym":"","interests":"Public Health, Research and Technology","euInitiatives":"Newron Pharmaceuticals SpA will be visiting Brussels to have meeting with various EU Institutions and agencies and intend to apply under Horizon 2020 Funding.","lastUp":"2017-04-27T17:10:35.788+01:00","customers":"","costAbsolu":"","costRange":"100000-199999","turnoverAbsolu":0,"turnoverRange":""}